What have we learnt from the recent reporting flurry? Societe Generale has put together a list of conclusions to be drawn from this earnings season.
Stocks rose on Monday as investors welcomed M&A and looked to the European Central Bank for further monetary easing moves.
European shares closed higher on Monday following a key speech by Mario Draghi, the president of the European Central Bank.
Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.
U.S. stock-index futures rose on Monday, following European shares higher, as traders digested comments by the Fed's Yellen and the ECB's Draghi.
Roche is buying biotech company InterMune for $74 per share, reports CNBC's Meg Tirrell.
Surani Fernando, EMEA deputy editor at Biopharm Insight, says she was "surprised" at the value of Roche's $8.3 billion purchase of Intermune.
Biotech firm Roche announced plans Sunday to buy InterMune for $8.3 billion on a fully diluted basis in an all-cash transaction.
Asian equities traded mixed on Monday as a cautious sentiment set in after fresh conflict in Ukraine at the weekend.
Chugai shares rose 21 percent following a media report that Roche Holding AG is in talks to buy the almost 40 percent stake in the Japanese firm.
Milind Sabnis, Associate Director for Healthcare Practice at Frost & Sullivan, discusses news that Roche is looking to acquire Japanese drug giant Chugai Pharmaceutical for about $10 billion.
U.S. stocks ended the week mixed after news of fresh conflict between Russia and Ukraine.
Take a look at some of Friday's midday movers:
Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.
Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.
European shares closed higher on Thursday, after a business activity index showed the euro zone rebounded in July.
Roche confirmed its full-year outlook, but posted profit that missed expectations following an impairment charge at its diagnostics business.
Severin Schwan, CEO of Roche, says the company would consider a large acquisition if the "price is right" despite concerns over high valuations.
Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.
Some of Monday's midday movers: